Representation and outcomes for older patients in phase 3 clinical trials for metastatic and unresectable head and neck squamous cell carcinoma (HNSCC): A systematic review. This is an ASCO Meeting ...

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell ...

Postoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.” ...

CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in ...

Adding nivolumab to adjuvant CRT improved DFS in patients with locally advanced head and neck squamous cell carcinoma at high risk of relapse.

About 40 percent of cancer cases are considered preventable. Try these lifestyle changes to stay healthy.

Gastroesophageal reflux disease and upper aerodigestive tract cancer risk: A meta-analysis of site-specific associations. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

In the Phase 1/1b trial, ficerafusp alfa in combination with pembrolizumab resulted in deep and durable anti-tumor activity with improved overall survival (OS) compared to historical benchmarks in ...

Immunotherapies are undoubtedly transforming the landscape of cancer treatment worldwide. By harnessing the body's immune ...

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with ...